Respiratory Virus InfectionNCT02538770
Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization
A study testing Rapid diagnostics using Anyplex TMII RV16 Detection and Delayed diagnostics Anyplex TMII RV16 Detection in people with Respiratory Virus Infection and Fever of Unknown Origin, run by University of Oulu at 2 sites in Finland.
Trial summary
Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Respiratory Virus Infection, Fever of Unknown Origin, Dyspnea
- What is being tested?
- Rapid diagnostics using Anyplex TMII RV16 Detection and Delayed diagnostics Anyplex TMII RV16 Detection
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 900 participants
- Where
- 2 sitesFinland
- Study dates
- Sep 2014to Nov 2015
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- All patients visiting Oulu University Hospital emergency room or admitted to acute pulmonology ward AND signs of possible respiratory tract infection such as cough, fever or dyspnea OR chest pain
Who cannot join
- No exclusion criteria
Trial locations and contacts
2 sites in 1 country.
Finland2 sites
Emergency Room of Oulu University Hospital
Oulu
Pulmonology ward Oulu University Hospital
Oulu
About this study
Official title: The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial
Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs.
A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed.
Read more
In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described.
The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.
Read the detailed description
Aim and Hypothesis
The aim of the study is:
- To find out how the modern rapid multiplex-PCR based respiratory virus detection method affects the patient care
- To examine does it shorten the length of admission and reduce antibiotic consumption
- Compare the seasonality of different viruses in children and adults
- Investigate the development and progress of an epidemic
- Study the differences in the prevalence and severity of infections between genders
- Describe clinical manifestations of different viral infections in adults
- View more closely certain subgroups such as patients with chest pain in respect to different viral epidemics and their effect on the hospital admission rates
- Evaluate the information provided by the bacterial detection
Subjects Our hospital is both a regional and a university hospital at the same time. Patients come to our clinic from a quite large area surrounding the city of Oulu and they represent the general population of the area well. The study population will be recruited 2014-2015 in the emergency clinics for pediatric and internal medicine patients in the Oulu University Hospital. Participants are patients with respiratory infection symptoms, chest pain or fever. Fever is determined as body temperature of 38 degrees centigrade or more measured either in the hospital or at home.
Study design This is a randomized clinical trial evaluating the impact of modern multiplex PCR based respiratory virus diagnostics on treatment and outcome of adult patients. Participants are randomized in two groups with results being reported either immediately or after a week (Picture 1). In children the viral PCR diagnostics is already routinely used and collection of nasal and pharyngeal samples continues normally. All pediatric results are reported immediately. Approval of the ethical review board of the Northern Ostrobothnia Hospital District has been acquired.
Course of the study Data collection All patients entering the internal medicine emergency clinics because of respiratory infection symptoms (cough, rhinitis, shortness of breath, sore throat), chest pain or fever will be given the opportunity to participate in the study. After signing an informed consent a nasal and a pharyngeal swab will be taken for viral examination. Adult patients are randomized in two different groups. In one group the results of the viral detection are reported immediately and in the other group they are reported 7 days after sampling.
Samples will be analyzed in the microbiological laboratory by real time PCR method Anyplex TMII to detect genome of 16 different respiratory viruses and of 5 different bacterial pathogen (Table 1). Results in the delayed group will be given earlier in the case the clinician is requesting them. The results of the bacterial findings will be analyzed after completion of the study since the clinical relevance of them is not clear yet. The bacteriological diagnostic of the patients during the study relies on the routinely used methods.
The attending clinician decides the treatment and care of the patient independently. Patient's chart will be reviewed for the course of disease, antibiotic use, ICU care and length of hospital stay. The results of key laboratory tests and microbiological findings will be collected. Radiological findings will be registered. At discharge, the participants are asked to report the duration of the symptoms, absence from work and the date of a possible doctors follow up. The population register centre will be used at the end of the study to find out the number of deceased, and their time and cause of the death will be recorded
. Table 1. Microbes detected from the study samples Viruses (AnyplexTMII RV16 Detection) Adenovirus Influenza A/B virus Parainfluenza virus1/2/3/4 Rhinovirus A/B/C Respiratory syncytial virus A/B Bocavirus 1/2/3/4 Metapneumovirus Coronavirus 229E/NL63/OC43 Enterovirus
Data analysis The length of hospital admission and the use of bacterial antibiotics is compared between the randomized groups. Viral findings of children and adults will be evaluated. The emergence of viruses in different areas of the district as well as in different age groups is examined. The differences in clinical picture and in microbiological findings between genders are viewed. The symptoms and clinical findings in adults with detected RSV or metapneumovirus are described. The bacterial findings are evaluated and compared with clinical data to determine the significance of the information provided by the test.
Impact of the study In our hospital major part of the viral respiratory infection diagnostics in adults has been accomplished by influenza virus antigen detection. Now a more sensitive measure for detecting 16 different respiratory pathogens from nasopharyngeal sample is available. We will determine whether more specific identification of the etiological agent affects the patient care. If the accurate diagnostics diminishes inappropriate antibiotic use it saves the patient from potential side effects and the society from unnecessary costs. Importantly it also saves the microbial flora from the antibiotic selection pressure which is considered to facilitate the emergence of antibiotic resistance. In children the benefits of accurate diagnostics have been recognized but in adults this is still under progress. This study is designed to demonstrate these advantages in adults.
- Being tested
- Rapid diagnostics using Anyplex TMII RV16 Detection, Delayed diagnostics Anyplex TMII RV16 Detection
- Medical subject headings
- Fever of Unknown Origin, Dyspnea, Chest Pain
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rapid diagnostics using Anyplex TMII RV16 DetectionOther
Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
Delayed diagnostics Anyplex TMII RV16 DetectionOther
Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
| Study group | Role | What they receive |
|---|---|---|
| Rapid Anyplex TMII RV16 Detection | Experimental | Intervention is the rapid performance of Anyplex TMII RV16 detection Receives: Other: Rapid diagnostics using Anyplex TMII RV16 Detection |
| Delayed Anyplex TMII RV16 Detection | Active comparator | Comprative intervention is the delayed performance of Anyplex TMII RV16 detection Receives: Other: Delayed diagnostics Anyplex TMII RV16 Detection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration of hospitalization
The number of days in hospital within one month after randomization
Measured: One month
Antimicrobial consumption
Number of days on antimicrobials within one month after randomization
Measured: One month
Antimicrobial consumption
Defined daily doses of antimicrobial agents within one month after randomization
Measured: One month
Secondary outcomes (2)
Number of radiological examinations
Measured: One month
Cost of other examinations in hospital
Measured: One month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Sep 2015 (estimated)
- Study startSep 2014
- Primary completionNov 2015
- Study completionNov 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Respiratory Virus InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 900 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Oulu
- Sponsor type
- University, hospital or other
- Collaborators
- Oulu University Hospital
- Responsible party
- Sponsor
- Investigators
- Marjo Renko, PhD, MD, Principal investigator, Oulu University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02538770
- Sponsor's protocol ID
- PPSHP93/2014
- Status last verified
- Jan 2016
- First submitted
- 31 Aug 2015
- Last updated
- 11 Jan 2016
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Jan 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT02538770
- Acronym / sponsor ID
- PPSHP93/2014
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 900 participants (actual)
- Lead sponsor
- University of OuluUniversity, hospital or other
- Collaborators
- Oulu University Hospital
- Study start
- Sep 2014
- Primary completion
- Nov 2015 (actual)
- Study completion
- Nov 2015 (actual)
- First posted
- 2 Sep 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Viral respiratory infections are common and often require use of health care resources. Patients receive inappropriate bacterial antibiotics, which has many problems including side-effects, development of resistance and costs.
A small portion of the infections leads to severe clinical manifestations including hospitalisations and deaths. The significance of influenza virus is well known and it is actively detected in all age groups. However, the benefits of detecting other respiratory viruses have mainly been studied among children but not among adults. The development of multiplex PCR technique has provided a new and sensitive method for diagnosing a large panel of viruses. To convince the economical benefits of the rapid viral diagnostic in adult infectious patient, more evidence is needed.
In our randomized study, nasal and pharyngeal samples from the patients evaluated at the emergency clinic of internal medicine in the University Hospital of Oulu because of any respiratory symptom, chest pain or fever, will be collected. The samples will be tested for 16 different respiratory viruses by using Anyplex TMII RV16 Detection. The adult participants will be randomized in two groups. In one group the results of the testing will be reported for the attending physician as soon as possible, and in the other group 7 days after sampling. The effect of this delay to patient care is monitored. Also the results of children and adults are compared as well as results of men and women. The hypothesis is that rapid viral diagnostics shortens the length of admission and diminishes the use of bacterial antibiotics. New information on the viral epidemiology among children and adults is provided and clinical manifestations of specific viral infections in adults are described.
The estimated 1500 samples are also tested for 5 different respiratory bacteria by Anyplex TM II RB5 Detection. These results will be examined after completion of the study period. The benefits of rapid bacterial detection are evaluated in respect to the clinical course of the disease and considering the infection control aspects as well.
Detailed description
Aim and Hypothesis
The aim of the study is:
- To find out how the modern rapid multiplex-PCR based respiratory virus detection method affects the patient care
- To examine does it shorten the length of admission and reduce antibiotic consumption
- Compare the seasonality of different viruses in children and adults
- Investigate the development and progress of an epidemic
- Study the differences in the prevalence and severity of infections between genders
- Describe clinical manifestations of different viral infections in adults
- View more closely certain subgroups such as patients with chest pain in respect to different viral epidemics and their effect on the hospital admission rates
- Evaluate the information provided by the bacterial detection
Subjects Our hospital is both a regional and a university hospital at the same time. Patients come to our clinic from a quite large area surrounding the city of Oulu and they represent the general population of the area well. The study population will be recruited 2014-2015 in the emergency clinics for pediatric and internal medicine patients in the Oulu University Hospital. Participants are patients with respiratory infection symptoms, chest pain or fever. Fever is determined as body temperature of 38 degrees centigrade or more measured either in the hospital or at home.
Study design This is a randomized clinical trial evaluating the impact of modern multiplex PCR based respiratory virus diagnostics on treatment and outcome of adult patients. Participants are randomized in two groups with results being reported either immediately or after a week (Picture 1). In children the viral PCR diagnostics is already routinely used and collection of nasal and pharyngeal samples continues normally. All pediatric results are reported immediately. Approval of the ethical review board of the Northern Ostrobothnia Hospital District has been acquired.
Course of the study Data collection All patients entering the internal medicine emergency clinics because of respiratory infection symptoms (cough, rhinitis, shortness of breath, sore throat), chest pain or fever will be given the opportunity to participate in the study. After signing an informed consent a nasal and a pharyngeal swab will be taken for viral examination. Adult patients are randomized in two different groups. In one group the results of the viral detection are reported immediately and in the other group they are reported 7 days after sampling.
Samples will be analyzed in the microbiological laboratory by real time PCR method Anyplex TMII to detect genome of 16 different respiratory viruses and of 5 different bacterial pathogen (Table 1). Results in the delayed group will be given earlier in the case the clinician is requesting them. The results of the bacterial findings will be analyzed after completion of the study since the clinical relevance of them is not clear yet. The bacteriological diagnostic of the patients during the study relies on the routinely used methods.
The attending clinician decides the treatment and care of the patient independently. Patient's chart will be reviewed for the course of disease, antibiotic use, ICU care and length of hospital stay. The results of key laboratory tests and microbiological findings will be collected. Radiological findings will be registered. At discharge, the participants are asked to report the duration of the symptoms, absence from work and the date of a possible doctors follow up. The population register centre will be used at the end of the study to find out the number of deceased, and their time and cause of the death will be recorded
. Table 1. Microbes detected from the study samples Viruses (AnyplexTMII RV16 Detection) Adenovirus Influenza A/B virus Parainfluenza virus1/2/3/4 Rhinovirus A/B/C Respiratory syncytial virus A/B Bocavirus 1/2/3/4 Metapneumovirus Coronavirus 229E/NL63/OC43 Enterovirus
Data analysis The length of hospital admission and the use of bacterial antibiotics is compared between the randomized groups. Viral findings of children and adults will be evaluated. The emergence of viruses in different areas of the district as well as in different age groups is examined. The differences in clinical picture and in microbiological findings between genders are viewed. The symptoms and clinical findings in adults with detected RSV or metapneumovirus are described. The bacterial findings are evaluated and compared with clinical data to determine the significance of the information provided by the test.
Impact of the study In our hospital major part of the viral respiratory infection diagnostics in adults has been accomplished by influenza virus antigen detection. Now a more sensitive measure for detecting 16 different respiratory pathogens from nasopharyngeal sample is available. We will determine whether more specific identification of the etiological agent affects the patient care. If the accurate diagnostics diminishes inappropriate antibiotic use it saves the patient from potential side effects and the society from unnecessary costs. Importantly it also saves the microbial flora from the antibiotic selection pressure which is considered to facilitate the emergence of antibiotic resistance. In children the benefits of accurate diagnostics have been recognized but in adults this is still under progress. This study is designed to demonstrate these advantages in adults.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Rapid Anyplex TMII RV16 Detection | Experimental | Other: Rapid diagnostics using Anyplex TMII RV16 DetectionIntervention is the rapid performance of Anyplex TMII RV16 detection |
| Delayed Anyplex TMII RV16 Detection | Active comparator | Other: Delayed diagnostics Anyplex TMII RV16 DetectionComprative intervention is the delayed performance of Anyplex TMII RV16 detection |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- All patients visiting Oulu University Hospital emergency room or admitted to acute pulmonology ward AND signs of possible respiratory tract infection such as cough, fever or dyspnea OR chest pain
Key exclusion criteria (1 listed)
- No exclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rapid diagnostics using Anyplex TMII RV16 DetectionRapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available | Other | Rapid Anyplex TMII RV16 Detection |
| Delayed diagnostics Anyplex TMII RV16 DetectionDelayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited | Other | Delayed Anyplex TMII RV16 Detection |
Primary outcome
Duration of hospitalization
Time frame: One month
The number of days in hospital within one month after randomization
Antimicrobial consumption
Time frame: One month
Number of days on antimicrobials within one month after randomization
Antimicrobial consumption
Time frame: One month
Defined daily doses of antimicrobial agents within one month after randomization
2 secondary outcomes
Number of radiological examinations
Time frame: One month
Cost of other examinations in hospital
Time frame: One month
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jan 2016.
Related trials for Respiratory Virus Infection
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
RecruitingPhase 3
Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease
Respiratory Syncytial Virus (RSV)
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Marjo Renko, PhD, MD principal investigator
Oulu University Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rapid diagnostics using Anyplex TMII RV16 Detection and Delayed diagnostics Anyplex TMII RV16 Detection in people with Respiratory Virus Infection and Fever of Unknown Origin, run by University of Oulu at 2 sites in Finland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Jan 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration of hospitalization (time frame: One month). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jan 2016.